StreetInsider.com News Articles

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

CD37 is a transmembrane protein that plays a role in regulating cell survival and is overexpressed on malignant B-cells, making it a promising therapeutic target.1 Currently, there are no CD37 directed therapies approved for any type of cancer.

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Wed, 04 Feb 2026 07:00:00 -0500

DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568).

“The initiation of this trial of DS3790 with its

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Tue, 03 Feb 2026 02:30:00 -0500

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population
If approved, DATROWAY could become the standard of care in this setting

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug